⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

Abbott Laboratories maintained a stable risk factor structure between 2024 and 2025, with 18 unchanged risks and 3 substantively modified risks, while adding and removing no risk categories. The three modified risks focused on healthcare regulatory environment impacts on product demand and pricing, public health crisis risks including infectious disease outbreaks, and research and development efforts to develop commercially successful products and technologies. This continuity suggests Abbott's core risk profile remained consistent year-over-year, with refinements limited to existing risk disclosures rather than identification of new or elimination of previous risk categories.

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

🟡 Modified Changes in the healthcare regulatory environment may adversely impact the demand for and price of Abbott’s products. 🔒

🟡 Modified Abbott is subject to risks related to public health crises, such as widespread outbreaks of infectious diseases, which could have a material effect on Abbott’s business, financial condition and results of operations. 🔒

🟡 Modified Abbott’s research and development efforts to develop commercially successful products and technologies and its efforts to develop and maintain new business and operating models necessary to support data-driven healthcare solutions may not succeed, either of which may cause Abbott’s revenue and profitability to decline. 🔒

3 changes in this historical filing

Historical year-over-year comparisons (2025 vs 2024 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →